Opioid Addiction Treatment Co. Nabs $110M For New Product
Braeburn Pharmaceuticals Inc. on Thursday said investors contributed $110 million to a recent funding round as the biotechnology firm targets regulatory approvals and commercialization of the company's latest opioid addiction treatment....To view the full article, register now.
Already a subscriber? Click here to view full article